Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy.

Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical process, ongoing trials, management and experiences of this treatment being developed specifically for veterinary use in dogs will be discussed during the 30‐minute presentation.

More data from the study is expected to be presented at the ACVIM Forum in June.

ELIAS Animal Health has applied for conditional licensure of its autologous cancer immunotherapy for the treatment of dogs with osteosarcoma with the United States Department of Agriculture (USDA) Center for Veterinary Biologics.

“We’re very excited to be selected by VCS for its state of the art presentation,” says Tammie Wahaus, chief executive officer, ELIAS Animal Health. “Being recognized by this distinguished group is a significant milestone for our unique treatment protocol and underscores the unmet medical need that these personalized immunotherapies can address in the fight against cancer.”

Media contact:
Susan Wright

Veterinarians interested in more information on the clinical program, please visit www.eliasanimalhealth.com or contact ELIAS at clinicaltrials@eliasah.com. Interested investors may contact info@eliasah.com.

About ELIAS Animal Health Based in Olathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy is being distributed to veterinarians under 9 CFR 103.3 as an experimental product. The company’s novel therapeutic approach offers the promise of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. For more information, please visit www.eliasanimalhealth.com.